Compare Stocks → Make This $3 Trade the Instant the Opening Bell Rings (From Monument Traders Alliance) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:EVFMNASDAQ:GERNNASDAQ:KALVNASDAQ:KMDANASDAQ:NERV 1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEVFMEvofem Biosciences$0.02$0.03$0.01▼$5.00$840K-1.191.18 million shs375,355 shsGERNGeron$3.18-5.6%$2.07$1.64▼$3.73$1.83B0.5517.67 million shs24.79 million shsKALVKalVista Pharmaceuticals$11.99+0.5%$13.75$6.26▼$16.88$503.31M0.9787,957 shs560,270 shsKMDAKamada$5.87+4.8%$5.93$4.08▼$6.53$321.86M1.0525,911 shs25,139 shsNERVMinerva Neurosciences$2.70-3.2%$6.74$1.56▼$13.49$19.51M0.22287,722 shs40,771 shs(Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEVFMEvofem Biosciences0.00%-15.09%-43.39%-70.81%-98.93%GERNGeron-5.51%+48.36%+57.96%+38.04%+25.49%KALVKalVista Pharmaceuticals+0.50%-8.47%-19.31%+8.41%+62.25%KMDAKamada+4.82%+2.80%-4.24%-1.84%+38.77%NERVMinerva Neurosciences-3.23%-3.91%-67.82%-59.40%+68.75%The world’s greatest investment (Ad)I believe this could change your life forever. I’m talking about transforming everything for you, financially. You see, a rare market anomaly has emerged that I believe is going to make some people very wealthy. Almost nobody in the mainstream media or Wall Street has connected the dots on what’s going on, but that ignorance won’t last for long. When they wake up to this situation, billions of dollars will flood in.Click here now to sign upMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEVFMEvofem BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AGERNGeron3.3084 of 5 stars3.51.00.01.53.01.70.6KALVKalVista Pharmaceuticals3.9629 of 5 stars3.51.00.04.52.32.50.6KMDAKamada3.9103 of 5 stars3.53.00.00.03.01.73.1NERVMinerva Neurosciences3.5092 of 5 stars3.03.00.04.62.30.80.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEVFMEvofem Biosciences2.00HoldN/AN/AGERNGeron3.00Buy$5.3367.98% UpsideKALVKalVista Pharmaceuticals3.00Buy$26.33119.63% UpsideKMDAKamada3.00Buy$11.0087.39% UpsideNERVMinerva Neurosciences2.00Hold$11.00307.41% UpsideCurrent Analyst RatingsLatest KMDA, NERV, GERN, KALV, and EVFM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/15/2024GERNGeronWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$6.003/15/2024GERNGeronThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.00 ➝ $5.003/15/2024GERNGeronNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.00 ➝ $5.003/7/2024KMDAKamadaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.002/28/2024GERNGeronNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.002/27/2024NERVMinerva NeurosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$11.002/14/2024KALVKalVista PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$16.00 ➝ $24.002/13/2024KALVKalVista PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$22.00 ➝ $35.00(Data available from 3/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEVFMEvofem Biosciences$16.84M0.05N/AN/A($62.94) per share0.00GERNGeron$240K7,223.92N/AN/A$0.46 per share6.90KALVKalVista PharmaceuticalsN/AN/AN/AN/A$4.71 per shareN/AKMDAKamada$142.52M2.37$0.45 per share13.13$4.25 per share1.38NERVMinerva NeurosciencesN/AN/AN/AN/A($4.07) per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEVFMEvofem Biosciences-$76.70MN/A0.00∞N/A344.82%-77.85%237.94%4/26/2024 (Estimated)GERNGeron-$184.13M-$0.33N/AN/AN/A-77,691.14%-63.33%-44.71%5/9/2024 (Estimated)KALVKalVista Pharmaceuticals-$92.91M-$3.15N/AN/AN/AN/A-86.06%-72.65%7/5/2024 (Estimated)KMDAKamada$8.28M$0.1539.1314.32N/A5.81%5.66%3.57%5/22/2024 (Estimated)NERVMinerva Neurosciences-$30M-$4.65N/AN/AN/AN/AN/A-50.27%5/20/2024 (Estimated)Latest KMDA, NERV, GERN, KALV, and EVFM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/28/2024Q4 23GERNGeron-$0.10-$0.09+$0.01-$0.09$0.06 million$0.02 million 2/22/2024Q4 2023NERVMinerva Neurosciences-$0.88-$1.19-$0.31-$1.19N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEVFMEvofem BiosciencesN/AN/AN/AN/AN/AGERNGeronN/AN/AN/AN/AN/AKALVKalVista PharmaceuticalsN/AN/AN/AN/AN/AKMDAKamadaN/AN/AN/AN/AN/ANERVMinerva NeurosciencesN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEVFMEvofem BiosciencesN/A0.170.13GERNGeron0.143.163.16KALVKalVista PharmaceuticalsN/A5.445.44KMDAKamadaN/A3.431.64NERVMinerva NeurosciencesN/A12.5712.58OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEVFMEvofem BiosciencesN/AGERNGeron65.44%KALVKalVista PharmaceuticalsN/AKMDAKamada34.08%NERVMinerva Neurosciences55.11%Insider OwnershipCompanyInsider OwnershipEVFMEvofem Biosciences0.21%GERNGeron3.10%KALVKalVista Pharmaceuticals12.30%KMDAKamada36.10%NERVMinerva Neurosciences6.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableEVFMEvofem Biosciences3545.03 million44.93 millionNot OptionableGERNGeron141546.06 million529.13 millionOptionableKALVKalVista Pharmaceuticals11842.19 million37.00 millionOptionableKMDAKamada38057.47 million36.73 millionOptionableNERVMinerva Neurosciences96.99 million6.55 millionNot OptionableKMDA, NERV, GERN, KALV, and EVFM HeadlinesSourceHeadlineF|T: The FinTech Times – Minerva chases anti-money laundering big leaguesbetakit.com - March 18 at 7:55 PMBMS completes $14bn takeover of Karunapharmaphorum.com - March 18 at 7:55 PMMinerva Porras, 86riverheadlocal.com - March 17 at 12:39 PMSocial factors taskforce launches guidance with support from Minervamanifest.co.uk - March 15 at 1:01 PMPotts Point homelessness encampment moved on from Minerva-Metro Theatre sitemsn.com - March 14 at 9:56 PMMinerva Named "One to Watch" in Chartis Financial Crime and Compliance 50 Rankingstmcnet.com - March 14 at 9:56 PMRenovated Manti Temple, preserved Minerva Teichert murals ready for 3-week public open housemsn.com - March 13 at 10:46 PMPotts Point homelessness encampment moved on by Minerva-Metro Theatre developer ownersnews.com.au - March 13 at 10:46 PMMinerva Named Top AI & Data Product in the 2024 Product Awardstmcnet.com - March 13 at 12:45 PMAcadia pulls trials of pimavanserin after schizophrenia failpharmaphorum.com - March 12 at 8:51 AMFDA Delays Approval of Roluperidone for Schizophrenia Treatmentmedindia.net - February 29 at 3:38 PMFDA Denies Approval of Roluperidone for Negative Symptoms of Schizophreniaempr.com - February 28 at 6:41 PMMinerva slumps as FDA finds fault with schizophrenia filingpharmaphorum.com - February 28 at 8:40 AMMinerva hit with FDA rejection for schizophrenia symptom drugpharmaceutical-technology.com - February 28 at 8:40 AMHold Rating on Minerva Neurosciences Amid FDA Setbacks and Financial Constraintsmarkets.businessinsider.com - February 27 at 7:53 PMMinerva schizophrenia drug rejected by FDAfinance.yahoo.com - February 27 at 2:50 PMFDA Turns Away Minerva's Roluperidone Schizophrenia Drugmarketwatch.com - February 27 at 2:50 PMMinerva Neurosciences Shares Slide on Latest FDA Roluperidone Setbackmorningstar.com - February 27 at 2:50 PMRegulatory Setback For Minerva Neurosciences' Schizophrenia Treatment Candidate, FDA Asks For More Datamsn.com - February 27 at 2:50 PMMinerva falls as FDA rejects schizophrenia therapymsn.com - February 27 at 2:50 PMMinerva again tangled in web of rejection after FDA nixes schizophrenia drug for 2nd timefiercebiotech.com - February 27 at 2:50 PMFDA rejects Burlington biotech’s schizophrenia drug, sends stock tumblingbizjournals.com - February 27 at 2:50 PMUS FDA declines to approve Minerva Neurosciences' schizophrenia drugreuters.com - February 27 at 8:21 AMMinerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophreniafinance.yahoo.com - February 27 at 8:21 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesHow to Invest in Artificial Intelligence in These Simple WaysMarch 7, 2024 1:08 PMView How to Invest in Artificial Intelligence in These Simple Ways5 Under-the-Radar Artificial Intelligence (AI) Stocks March 4, 2024 9:30 AMView 5 Under-the-Radar Artificial Intelligence (AI) Stocks Can UnitedHealth Group afford to keep Medicare Advantage plans?February 19, 2024 6:15 AMView Can UnitedHealth Group afford to keep Medicare Advantage plans?Your Comprehensive Guide to Investing in Bank StocksMarch 1, 2024 10:41 AMView Your Comprehensive Guide to Investing in Bank StocksKroger Stock: Anticipating New Highs as Promising Uptrend ResumesMarch 12, 2024 7:30 AMView Kroger Stock: Anticipating New Highs as Promising Uptrend ResumesAll Headlines Company DescriptionsEvofem BiosciencesNASDAQ:EVFMEvofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women; and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.GeronNASDAQ:GERNGeron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.KalVista PharmaceuticalsNASDAQ:KALVKalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.KamadaNASDAQ:KMDAKamada Ltd., together with its subsidiaries, provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. It has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. Kamada Ltd. was incorporated in 1990 and is headquartered in Rehovot, Israel.Minerva NeurosciencesNASDAQ:NERVMinerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.